MétaCan
Menu
Back to cohort
Record W4293755994 · doi:10.22207/jpam.16.3.75

Monkeypox Vaccines: Current Update

2022· article· en· W4293755994 on OpenAlexaboutno aff
V. Sangamithra, P. Sneka, K.P. Hamsadwani

Bibliographic record

VenueJournal of Pure and Applied Microbiology · 2022
Typearticle
Languageen
FieldImmunology and Microbiology
TopicPoxvirus research and outbreaks
Canadian institutionsnot available
Fundersnot available
KeywordsMonkeypoxVacciniaSmallpoxOrthopoxvirusVirologySmallpox vaccineCowpoxVaccinationMedicinePoxviridaeBiology

Abstract

fetched live from OpenAlex

Monkeypox belonging to the genus Orthopoxvirus (OPV) of the family poxviridiae poses a major human threat even after 30 years after eradicating smallpox. OPV family includes other viruses like vaccinia virus (VACV), variola virus and cowpox virus. VACV smallpox vaccine provided cross protective antibody response against other orthopox viruses.1 The ongoing monkeypox outbreak has affected 31,800 people in more than 89 different countries. India has documented 9 confirmed cases with one death reported.2 Stockpile of smallpox vaccines that contain live vaccinia virus is maintained at two locations, one at Centre for Disease Control laboratory at Atlanta, Georgia and the other at VECTOR institute, Koltsovo, Russia. Data shows effectiveness of Smallpox vaccines against monkeypox to be 85%.3 Vaccine used in smallpox eradication were first generation vaccines which produced multiple side effects like eczema, progressive vaccinia and myopericarditis. This fear of adverse effects and safety concerns had led to the production of second and third generation vaccines like imvanex or ACAM2000.4 The interim guidelines for monkeypox vaccination does not urge the need for mass vaccination considering the side effects and the vaccine production. Countries like Canada, United Kingdom and USA are using ring vaccination to prevent monkeypox. The two vaccines currently being used against monkeypox are Jynneos vaccine and ACAM2000.5 JYNNEOS vaccine (Imvamune in Canada /Imvanex in Europe developed by Bavarian Nordiac) for adults aged 18 years and older was approved in Europe and U.S. The vaccine contains a replication deficient live vaccinia virus (Modified vaccinia Ankara-MVA BN) that is given as subcutaneous injection of 0.5 ml, two doses four weeks apart. The vaccine is used for post exposure prophylaxis against monkeypox virus. CDC recommends the intermediate or high risk group as potential group to receive post exposure propylaxis of the vaccine (Unprotected contact with the body fluid of infected person or contact with less 6 meter distance with the infected person). Vaccine is available in countries like Canada, Europe and Britain.6 ACAM2OOO, containing live replicating vaccinia virus that can replicate as compared to jynneos vaccine. Owning to the side effects associated with the vaccine its only used for laboratory workers handling pox viruses or for military personnel.4,7,8 WHO has stated there is no need for mass vaccination and decision regarding vaccination should be based on the individual case accessing the risk and benefits.5 In India, the Serum Institute of India has confirmed its ongoing research to find vaccine against monkeypox. Monkeypox vaccine pipelines include 1. Tonix Pharmaceuticals Holding Corp TNX-8011, a preclinical live virus, which uses horsepox virus 2. EpiVax, Inc’s-Epitome driven vaccine 3. VennVax, DNA prime peptide boost multi-T cell epitome Pox virus vaccine.9

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.887
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.252
Teacher spread0.241 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Pure and Applied MicrobiologySame topicPoxvirus research and outbreaksFrench-language works237,207